168 related articles for article (PubMed ID: 38698847)
1. Antioxidant network-based signatures cluster glioblastoma into distinct redox-resistant phenotypes.
Yang Y; More S; De Smet F; De Vleeschouwer S; Agostinis P
Front Immunol; 2024; 15():1342977. PubMed ID: 38698847
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
[TBL] [Abstract][Full Text] [Related]
3. Quiescent stem cell marker genes in glioma gene networks are sufficient to distinguish between normal and glioblastoma (GBM) samples.
Mukherjee S
Sci Rep; 2020 Jul; 10(1):10937. PubMed ID: 32616845
[TBL] [Abstract][Full Text] [Related]
4. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment.
Tejero R; Huang Y; Katsyv I; Kluge M; Lin JY; Tome-Garcia J; Daviaud N; Wang Y; Zhang B; Tsankova NM; Friedel CC; Zou H; Friedel RH
EBioMedicine; 2019 Apr; 42():252-269. PubMed ID: 30952620
[TBL] [Abstract][Full Text] [Related]
5. Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma.
Correa BR; de Araujo PR; Qiao M; Burns SC; Chen C; Schlegel R; Agarwal S; Galante PA; Penalva LO
Genome Biol; 2016 Jun; 17(1):125. PubMed ID: 27287018
[TBL] [Abstract][Full Text] [Related]
6. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
7. Nuclear respiratory factor 1 transcriptomic signatures as prognostic indicators of recurring aggressive mesenchymal glioblastoma and resistance to therapy in White American females.
Bhawe K; Das JK; Yoo C; Felty Q; Gong Z; Deoraj A; Liuzzi JP; Ehtesham NZ; Hasnain SE; Singh VP; Mohapatra I; Komotar RJ; Roy D
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1641-1682. PubMed ID: 35441887
[TBL] [Abstract][Full Text] [Related]
8. Identification of candidate biomarkers for GBM based on WGCNA.
Sun Q; Wang Z; Xiu H; He N; Liu M; Yin L
Sci Rep; 2024 May; 14(1):10692. PubMed ID: 38724609
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
[TBL] [Abstract][Full Text] [Related]
10. GRPEL2 Knockdown Exerts Redox Regulation in Glioblastoma.
Tang CT; Li YF; Chou CH; Huang LC; Huang SM; Hueng DY; Tsai CK; Chen YH
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884508
[TBL] [Abstract][Full Text] [Related]
11. Identification of Systems Level Molecular Signatures from Glioblastoma Multiforme Derived Extracellular Vesicles.
Roy N; Gaikwad M; Bhattacharrya DK; Barah P
J Mol Neurosci; 2021 Jun; 71(6):1156-1167. PubMed ID: 33231813
[TBL] [Abstract][Full Text] [Related]
12. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
Syafruddin SE; Nazarie WFWM; Moidu NA; Soon BH; Mohtar MA
BMC Cancer; 2021 Jul; 21(1):850. PubMed ID: 34301218
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics and machine learning methodologies to identify the effects of central nervous system disorders on glioblastoma progression.
Rahman MH; Rana HK; Peng S; Hu X; Chen C; Quinn JMW; Moni MA
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33406529
[TBL] [Abstract][Full Text] [Related]
14. Proteogenomics of glioblastoma associates molecular patterns with survival.
Yanovich-Arad G; Ofek P; Yeini E; Mardamshina M; Danilevsky A; Shomron N; Grossman R; Satchi-Fainaro R; Geiger T
Cell Rep; 2021 Mar; 34(9):108787. PubMed ID: 33657365
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
16. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
17. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
[TBL] [Abstract][Full Text] [Related]
18. Role of alternative splicing signatures in the prognosis of glioblastoma.
Xie ZC; Wu HY; Dang YW; Chen G
Cancer Med; 2019 Dec; 8(18):7623-7636. PubMed ID: 31674730
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential crucial genes and molecular mechanisms in glioblastoma multiforme by bioinformatics analysis.
Chen X; Pan Y; Yan M; Bao G; Sun X
Mol Med Rep; 2020 Aug; 22(2):859-869. PubMed ID: 32467990
[TBL] [Abstract][Full Text] [Related]
20. Identification of key genes involved in the recurrence of glioblastoma multiforme using weighted gene co-expression network analysis and differential expression analysis.
Ren P; Wang J; Li L; Lin X; Wu G; Chen J; Zeng Z; Zhang H
Bioengineered; 2021 Dec; 12(1):3188-3200. PubMed ID: 34238116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
